10 research outputs found
Supplementary data for: Missed Diagnoses and Health Problems in Adults With Prader-Willi Syndrome: Recommendations for Screening and Treatment
Context: Prader-Willi syndrome (PWS) is a complex hypothalamic disorder, combining
hyperphagia, hypotonia, intellectual disability, and pituitary hormone deficiencies.
Annual mortality of patients with PWS is high (3%). In half of the patients, the cause of
death is obesity related and/or of cardiopulmonary origin. Health problems leading to
this increased mortality often remain undetected due to the complexity and rareness of
the syndrome.
Objective: To assess the prevalence of health problems in adults with PWS retrospectively.
Patients, Design, and Setting: We systematically screened 115 PWS adults for
undiagnosed health problems. All patients visited the multidisciplinary outpatient clinic
for rare endocrine syndromes at the Erasmus University Medical Center, Rotterdam,
Netherlands. We collected the results of medical questionnaires, interviews, physical xaminations, biochemical measurements, polygraphy, polysomnography, and
radiology.
Main outcome measures: Presence or absence of endocrine and nonendocrine
comorbidities in relation to living situation, body mass index, genotype, and demographic
factors.
Results: Seventy patients (61%) had undiagnosed health problems, while 1 in every
4 patients had multiple undiagnosed health problems simultaneously. All males and
93% of females had hypogonadism, 74% had scoliosis, 18% had hypertension, 19% had
hypercholesterolemia, 17% had type 2 diabetes mellitus, and 17% had hypothyroidism.
Unfavorable lifestyles were common: 22% exercised too little (according to PWS criteria)
and 37% did not see a dietitian.
Conclusions: Systematic screening revealed many undiagnosed health problems in
PWS adults. Based on patient characteristics, we provide an algorithm for diagnostics
and treatment, with the aim to prevent early complications and reduce mortality in this
vulnerable patient group
Supplementary data for: Central adrenal insufficiency is rare in adults with Prader-Willi syndrome
Central Adrenal Insufficiency Is Rare in Adults With Prader-Willi Syndrome
CONTEXT: Prader-Willi syndrome (PWS) is associated with several hypothalamic-pituitary hormone deficiencies. There is no agreement on the prevalence of central adrenal insufficiency (CAI) in adults with PWS. In some countries, it is general practice to prescribe stress-dose hydrocortisone during physical or psychological stress in patients with PWS. Side effects of frequent hydrocortisone use are weight gain, osteoporosis, diabetes mellitus, and hypertension-already major problems in adults with PWS. However, undertreatment of CAI can cause significant morbidity-or even mortality. OBJECTIVE: To prevent both over- and undertreatment with hydrocortisone, we assessed the prevalence of CAI in a large international cohort of adults with PWS. As the synacthen test shows variable results in PWS, we only use the metyrapone test (MTP) and insulin tolerance test (ITT). DESIGN: Metyrapone test or ITT in adults with PWS (N = 82) and review of medical files for symptoms of hypocortisolism related to surgery (N = 645). SETTING: Outpatient clinic. PATIENTS OR OTHER PARTICIPANTS: Eighty-two adults with genetically confirmed PWS. MAIN OUTCOME MEASURE: For MTP, 11-deoxycortisol > 230 nmol/L was considered sufficient. For ITT, cortisol > 500 nmol/L (Dutch, French, and Swedish patients) or > 450 nmol/L (British patients) was considered sufficient. RESULTS: Central adrenal insufficiency was excluded in 81 of 82 patients. Among the 645 patients whose medical files were reviewed, 200 had undergone surgery without perioperative hydrocortisone treatment. None of them had displayed any features of hypocortisolism. CONCLUSIONS: Central adrenal insufficiency is rare (1.2%) in adults with PWS. Based on these results, we recommend against routinely prescribing hydrocortisone stress-doses in adults with PWS
Missed diagnoses and health problems in adults with prader-willi syndrome: Recommendations for screening and treatment
Context: Prader-Willi syndrome (PWS) is a complex hypothalamic disorder, combining
hyperphagia, hypotonia, intellectual disability, and pituitary hormone deficiencies.
Annual mortality of patients with PWS is high (3%). In half of the patients, the cause of
death is obesity related and/or of cardiopulmonary origin. Health problems leading to
this increased mortality often remain undetected due to the complexity and rareness of
the syndrome.
Objective: To assess the prevalence of health problems in adults with PWS retrospectively.
Patients, Design, and Setting: We systematically screened 115 PWS adults for
undiagnosed health problems. All patients visited the multidisciplinary outpatient clinic
for rare endocrine syndromes at the Erasmus University Medical Center, Rotterdam,
Netherlands. We collected the results of medical questionnaires, interviews, physical xaminations, biochemical measurements, polygraphy, polysomnography, and
radiology.
Main outcome measures: Presence or absence of endocrine and nonendocrine
comorbidities in relation to living situation, body mass index, genotype, and demographic
factors.
Results: Seventy patients (61%) had undiagnosed health problems, while 1 in every
4 patients had multiple undiagnosed health problems simultaneously. All males and
93% of females had hypogonadism, 74% had scoliosis, 18% had hypertension, 19% had
hypercholesterolemia, 17% had type 2 diabetes mellitus, and 17% had hypothyroidism.
Unfavorable lifestyles were common: 22% exercised too little (according to PWS criteria)
and 37% did not see a dietitian.
Conclusions: Systematic screening revealed many undiagnosed health problems in
PWS adults. Based on patient characteristics, we provide an algorithm for diagnostics
and treatment, with the aim to prevent early complications and reduce mortality in this
vulnerable patient group
Thyroid function in adults with prader–willi syndrome; a cohort study and literature review
Prader–Willi syndrome (PWS) is a complex genetic syndrome combining hypotonia, hy-perphagia, a PWS-specific neurocognitiv
Supplementary data for: Growth hormone treatment for adults with Prader-Willi syndrome - a meta-analysis
CONTEXT: Features of Prader-Willi syndrome (PWS) overlap with features of growth hormone (GH) deficiency, like small hands and feet, short stature, increased body fat, and low muscle mass and strength. In children with PWS, GH treatment (GHt) improves physical health and cognition. GHt has become the standard of care in PWS children, but in adults this is not yet the case. OBJECTIVE: This work aims to provide an overview of the current knowledge on GHt in PWS adults. METHODS: Medline, Embase, and the Cochrane Central Register of Controlled Trials databases were searched. Study selection included randomized clinical trials (RCTs) and nonrandomized (un)controlled trials (NRCTs) that reported data for adults with PWS, who received GHt for at least 6 months. Data on body composition, body mass index (BMI), cardiovascular end points, bone, cognitive function, quality of life, and safety were extracted. RESULTS: Nine RCTs and 20 NRCTs were included. Body composition improved during 12 months of GHt with an increase in mean (95% CI) lean body mass of 1.95 kg (0.04 to 3.87 kg) and a reduction of mean (95% CI) fat mass of –2.23% (–4.10% to –0.36%). BMI, low-density lipoprotein cholesterol levels, fasting glucose levels, and bone mineral density did not change during GHt. There were no major safety issues. CONCLUSION: GHt appears to be safe and improves body composition in adults with PWS. Because poor body composition is closely linked to the observed high incidence of cardiovascular morbidity in adults with PWS, improving body composition might reduce cardiovascular complications in this vulnerable patient group
The diagnostic journey of a patient with prader–willi-like syndrome and a unique homozygous snurf-snrpn variant; bio-molecular analysis and review of the literature
Prader–Willi syndrome (PWS) is a rare genetic condition characterized by hypotonia, intellectual disability, and hypothalamic dysfunction, causing pituitary hormone deficiencies and hyperphagia, ultimately leading to obesity. PWS is most often caused by the loss of expression of a cluster of genes on chromosome 15q11.2-13. Patients with Prader–Willi-like syndrome (PWLS) display features of the PWS phenotype without a classical PWS genetic defect. We describe a 46-year-old patient with PWLS, including hypotonia, intellectual disability, hyperphagia, and pituitary hormone deficiencies. Routine genetic tests for PWS were normal, but a homozygous missense variant NM_003097.3(SNRPN):c.193C>T, p.(Arg65Trp) was identified. Single nucleotide polymorphism array showed several large regions of homozygosity, caused by high-grade consanguinity between the parents. Our functional analysis, the ‘Pipeline for Rapid in silico, in vivo, in vitro Screening of Mutations’ (PRiSM) screen, showed that overexpression of SNRPN-p.Arg65Trp had a dominant negative effect, strongly suggesting pathogenicity. However, it could not be confirmed that the variant was responsible for the phenotype of the patient. In conclusion, we present a unique homozygous missense variant in SNURF-SNRPN in a patient with PWLS. We describe the diagnostic trajectory of this patient and the possible contributors to her phenotype in light of the current literature on the genotype–phenotype relationship in PWS.</p
Effects of childhood multidisciplinary care and growth hormone treatment on health problems in adults with prader-willi syndrome
Prader-Willi syndrome (PWS) is a complex hypothalamic disorder. Features of PWS include hyperphagia, hypotonia, intellectual disability, and pituitary hormone deficiencies. The combination of growth hormone treatment and multidisciplinary care (GHMDc) has greatly improved the health of children with PWS. Little is known about the effects of childhood GHMDc on health outcomes in adulthood. We retrospectively collected clinical data of 109 adults with PWS. Thirty-nine had received GHMDc during childhood and adolescence (GHMDc+ group) and sixty-three had never received growth hormone treatment (GHt) nor multidisciplinary care (GHMDc− group). Our systematic screening revealed fewer undetected health problems in the GHMDc+ group (10%) than in the GHMDc− group (84%). All health problems revealed in the GHMDc+ group had developed between the last visit to the paediatric and the first visit to the adult clinic and/or did not require treatment. Mean BMI and the prevalence of diabetes mellitus type 2 were significantly lower in the GHMDc+ group compared to the GHMDc− group. As all patients who received GHt were treated in a multidisciplinary setting, it is unknown which effects are the result of GHt and which are the result of multidisciplinary care. However, our data clearly show that the combination of both has beneficial effects. Therefore, we recommend continuing GHMDc after patients with PWS have reached adult age.</p